The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction by Brownstein, John Samuel et al.
 
The tell-tale heart: population-based surveillance reveals an
association of rofecoxib and celecoxib with myocardial infarction
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Brownstein, John S., Margarita Sordo, Isaac S. Kohane, and
Kenneth D. Mandl. 2007. The tell-tale heart: population-based
surveillance reveals an association of rofecoxib and celecoxib with
myocardial infarction. PLoS ONE 2(9): e840.
Published Version doi:10.1371/journal.pone.0000840
Accessed February 19, 2015 8:11:52 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4875879
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe Tell-Tale Heart: Population-Based Surveillance
Reveals an Association of Rofecoxib and Celecoxib with
Myocardial Infarction
John S. Brownstein
1,2,3*, Margarita Sordo
1,4, Isaac S. Kohane
1,3,5,6, Kenneth D. Mandl
1,2,3,5
1Children’s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, United States of
America, 2Division of Emergency Medicine, Children’s Hospital Boston, Boston, Massachusetts, United States of America, 3Department of Pediatrics,
Harvard Medical School, Boston, Massachusetts, United States of America, 4Decision Systems Group, Brigham and Women’s Hospital, Boston,
Massachusetts, United States of America, 5Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of
America, 6Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Background. COX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether
population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI.
Methodology/Principal Findings. We conducted a retrospective study of inpatients at two Boston hospitals, from January
1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per
100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one
year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due
to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for
MI when both rofecoxib and celecoxib were on the market (P,0.001). For every million prescriptions of rofecoxib and
celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related
hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and
rofecoxib (Spearman correlation, 20.67, P,0.05). Conclusions/Significance. The strong relationship between prescribing
and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI
appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to
pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market
withdrawal of rofecoxib.
Citation: Brownstein JS, Sordo M, Kohane IS, Mandl KD (2007) The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib
and Celecoxib with Myocardial Infarction. PLoS ONE 2(9): e840. doi:10.1371/journal.pone.0000840
INTRODUCTION
In the United States, almost a million people are hospitalized, and
200,000-300,000 die each year of myocardial infarction (MI).[1,2]
Rates of MI have increased over the last century and are
attributable to lifestyle risk factors, including smoking, obesity,
exercise and diet.[3,4,5] While non-cardiovascular target drugs
such as fenfluramine, dexfenfluramine, terfanadine and cisapride
have been shown to be risk factors for cardiovascular events
[6,7,8], their effects are rare and are not considered as contributors
to long term trends in morbidity and mortality.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasing-
ly implicated in cardiovascular morbidity [9] and Cyclooxygena-
se-2 (COX-2) selective inhibitors, a class of NSAIDs, have been,
in particular, associated with increased risk of MI.
[9,10,11,12,13,14,15,16] Rofecoxib was withdrawn from the
market after a randomized placebo-controlled trial revealed
increased cardiovascular risk in patients with colorectal
polyps.[17] Though similarly associated with cardiovascular risk
[9], celecoxib is still prescribed widely. Many studies have
supported an increased individual risk of MI, but the popula-
tion-level impact of COX-2 selective inhibitor prescription has not
been described or quantified despite their substantial market
penetration and delayed market withdrawal.
In this study, we elucidate long-term temporal trends in rates of
inpatient visits for MI to an integrated health system in Boston,
Massachusetts and their correspondence with prescriptions for
rofecoxib and celecoxib. We estimate the magnitude of this effect
on macro-level trends in hospitalizations for MI.
METHODS
Study Setting and Population
The patient population was from Partners Healthcare System,
a large multi-specialty group practice that provides care to
members of a New England–based health maintenance organiza-
tion. This non-profit, integrated health system includes Brigham
and Women’s Hospital and Massachusetts General Hospital. The
source of clinical data—patient demographic information, dates,
medication, and diagnosis information, and discharge summa-
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ized data warehouse. Institutional Review Board (IRB) approval
was obtained.
The study outcome was serious coronary heart disease, defined
as acute MI requiring hospitalization. Subjects were all patients
hospitalized for MI assigned by primary or admitting diagnosis
International Classification of Diseases, Ninth Revision (ICD-9)
code 410, from January 1 1997 to March 31 2006. This diagnostic
code has been validated by others and used as an indicator of
acute MI. [10,18,19] In our own chart review, we found that 87%
of patients assigned the code had strong confirmatory evidence of
acute MI. To calculate incidence, we estimated the denominator
by combining US Census population estimates for Massachusetts
from 1997–2005 with market share estimates for the two study
hospitals. Market share was calculated using data from the
Massachusetts Division of Health Care Finance and Policy (1999–
2004) which contains hospitalizations at all Massachusetts
hospitals. Mean yearly market share was estimated at 12.4%
(SD, 0.6%). To adjust for biases stemming from shifts in healthcare
utilization patterns and changes in health coverage and market
share, we also included total number of hospitalizations per unit
time as a covariate in our analyses.
Interrupted Time Series Analysis
Using a population monitoring framework, we tested for a change
in the population rate of MI after introduction of rofecoxib and
celecoxib using three time series analysis methods. The first was
cumulative sum (CUSUM), regularly used in industrial process
control. More recently it has been applied to the early detection of
disease outbreaks [20] and to adverse drug events.[21,22] The
CUSUM, a type of control chart, detects sudden changes in the
mean value of a quantity of interest and provides estimates of the
timing and magnitude of change.[23] Specifically, the analysis
calculates the cumulative sum of deviations from a set value in
successive samples. An alarm threshold value is defined a priori
taking into account an acceptable false alarm rate or average run
length. Here, we used CUSUM to define whether and when
a detectable rise in cardiovascular events could have been
identified by simply monitoring the time series of monthly rate
of inpatient stays for MI.
Second, we investigated the association of the market
availability of celecoxib (January 1999–present), and rofecoxib
(May 1999–September 2004) on the time series of the monthly
rate of inpatient stays for MI using generalized linear modeling.
We assumed a Poisson distribution for modeling counts of
independent MI events. The model included binary indicator
variables for rofecoxib and celecoxib (on or off the market), and
used estimated population covered as the offset. Seasonal trends in
MIs were adjusted for by including eleven months of the year as
indicator variables. We included monthly number of total
inpatient stays to adjust for potential secular trends in healthcare
utilization. A linear trend term was included to account for long-
term changes in MI-related hospitalizations. To account for
overdispersion in the count data, extra-Poisson variability was
modeled and incorporated into estimates of standard errors.[24]
Parameter estimates were transformed to rate ratios.
Finally, we matched fluctuations in yearly incidence of
hospitalizations due to MI to prescription data on rofecoxib and
celecoxib. Total numbers of prescriptions dispensed were obtained
from the freely available IMS Health annual report on Commonly
Requested Therapeutic Class and Product Information.[25] We
measured the impact of celecoxib and rofecoxib prescription rates
by fitting Poisson regression models as described above. In this
case, we modeled yearly counts of MIs, including total underlying
population as an offset, and overall number of yearly inpatient
stays as a model covariate. A linear trend term was included to
account for long-term secular trends.[26] Prescription counts for
celecoxib and rofecoxib were examined separately and in
combination. In addition to incidence, we also examined the
association between yearly changes in the mean patient age at time
of MI with prescription volume for rofecoxib. All analyses were
carried out using the SAS statistical software (version 9.0, SAS
Institute Inc., Cary, NC).
Anchor Diagnoses
To confirm that our results were not simply reflective of systematic
bias related to referral patterns and secular trends in acuity mix at
the two hospitals, we monitored yearly changes in three anchor
diagnoses. We investigated whether yearly incidence of hospita-
lizations due to abdominal aortic aneurysm (ICD-9 codes 441.3–
441.4), appendicitis (ICD-9 codes 441.3–441.4), and pneumonia
and influenza (ICD-9 codes 480–487) were coincident with MIs by
two-tailed Spearman rank correlation.
RESULTS
Study Population
We identified 25,486 unique patients who had 30,603 MI-related
hospitalizations during the study period. Monthly incidence of
hospitalizations due to MI ranged from 33.3 per 100,000 inpatient
stays in March of 2006 to 56.4 per 100,000 in December, 2002
(mean, 46.2; 95 percent confidence interval, 45.1 to 47.2).
Incidence of hospitalizations due to MI ranged from 48.8 per
10,000 in 1997 and 2005 to 62.3 per 10,000 in 2001.
Interrupted Time Series Analysis
Based on the mean and standard deviation of MI incidence for
a baseline period of 1997–1998, we first tested for cumulating
deviations above a target mean of 47.1 MI-related hospitalizations
per 100,000 and a standard deviation of 2.8 per 100,000. (Figure 1)
The threshold for CUSUM was calculated as 1.18, yielding an
average-run-length of 50. In other words, we set the false alarm
rate to once per 50 months. An aberration of two standard
deviations from baseline was initially detected in January of 2000,
with a CUSUM value of 1.37 and 51.5 MI-related hospitalizations
per 100,000 stays (9.3 percent above expected). This significant
rise was eight months after the market introduction of rofecoxib
and one year after the introduction of celecoxib. A second and
sustained rise began November of 2000 with a CUSUM value of
2.08 and 54.2 MI-related hospitalizations per 100,000 (16 percent
above expected). The exceedance peaked in March of 2003,
46 months after the introduction of rofecoxib with a CUSUM
value of 16.5. Threshold was exceeded for 48 consecutive months,
ending in October 2004, one month after the market withdrawal
of rofecoxib.
Second, we modeled the impact of market availability of
celecoxib and rofecoxib on inpatient stays for MIs. For celecoxib,
inpatient stays due to MI were 41.6 per 100,000 prior to the
December 1999 release (n=24 months; 95 percent confidence
interval, 40.4 to 42.8), and 47.4 from January 1999 to March 2006
(n=87 months; 95 percent confidence interval. 46.3 to 48.6). MI-
related hospitalizations were 41.7 per 100,000 over the period
prior to rofecoxib introduction and post-withdrawal
(n=47 months; 95 percent confidence interval, 40.7 to 42.7).
While rofecoxib was on the market, the rate of MI-related
hospitalizations was 49.4 per 100,000 (n=64 months; 95 percent
confidence interval. 48.3 to 50.5), an 18.5 percent increase. We
measured the effect of celecoxib and rofecoxib dispensing on the
COX-2 Inhibitors and MI
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where the two drugs were included as indicator variables. The
model for rofecoxib revealed a positive relationship with counts of
MIs (rate ratio 1.14; 95 percent confidence interval, 1.09 to 1.19;
P,0.001), explaining 28.7 percent of the deviance. The model for
celecoxib also revealed a significant positive relationship with
counts of MIs (rate ratio 1.09; 95 percent confidence interval, 1.01
to 1.18; P=0.022), explaining 5.2 percent of the deviance.
Finally, we measured the yearly impact of estimated celecoxib
and rofecoxib use on hospitalizations due to MIs as a dose-
response relationship using national prescription data (Table 1).
Prescriptions for celecoxib and rofecoxib peaked in 2001 with
25.41 and 27.06 million prescriptions dispensed nationally,
respectively. Incidence of MI-related hospitalizations also peaked
in 2001 with 62.3 hospitalizations per 10,000 (Figure 2). Yearly
counts of MIs were significantly predicted by prescriptions for
rofecoxib (0.7% increase in MIs per million prescriptions; 95
percent confidence interval, 0.2% to 1.3%) and marginally for
celecoxib (0.6% increase in MIs per million prescriptions, 95
percent confidence interval, 20.005% to 1.8%;). For every million
prescriptions of both rofecoxib and celecoxib, we found a 0.5
percent increase in MI (95 percent confidence interval, 0.1 to 0.9),
explaining approximately 50.3 percent of the deviance in yearly
variation of MI-related hospitalizations.
We also find a significant negative association between mean
patient age and prescriptions for celecoxib and rofecoxib
(Spearman correlation, 20.67, P,0.05). Over the years when
rofecoxib was not available, the mean age was 66.5 compared to
a mean age of 65.4 over the period of market availability. Figure 3
shows the nadir in age corresponding to the peak of rofecoxib and
celecoxib prescriptions.
Anchor Diagnoses
To demonstrate that our findings were not simply based on
changing healthcare utilization, we investigated temporal trends
for hospitalizations for three other diagnoses. Though showing
a positive linear increase, abdominal aortic aneurysm (Spearman
correlation, 0.17; P=0.66), appendicitis (Spearman correlation,
0.11; P=0.78), and pneumonia and influenza (Spearman
correlation, 0.071; P=0.86) were not associated with trends in
MI. Further, only trends in inpatient visits for MI were
significantly correlated with national prescription rates for
rofecoxib and celecoxib (Spearman correlation 0.93; P,0.001).
DISCUSSION
Our findings demonstrate striking longitudinal trends in the
population rate of MI and strongly suggest a population-level
impact of rofecoxib and celecoxib on MI. Temporal trends in
inpatient stays due to MIs are tightly coupled to the rise and fall of
prescription of COX-2 inhibitors, with an 18.5 percent increase in
inpatient stays for MI during the time when rofecoxib was on the
market. These results are consistent with prior reports demon-
strating cardiovascular effects of rofecoxib and celecoxib.
[9,10,11,12,13,14,15,17,27] Further, mean age at MI appears to
have been lowered by use of these medications.
Using population surveillance methods [28,29,30] we confirm
a sharp rise in adverse cardiovascular events within eight months
Figure 1. Cumulative sum (CUSUM) chart of monthly incidence of hospitalizations due to myocardial infarction from January 1, 1997 to March
30, 2006. Assigning 1997 and 1998 as a baseline period, a target mean of 47.1 hospitalizations due to myocardial infarctions per 100,000 and
a standard deviation of 2.8 per 100,000.The threshold for CUSUM was calculated as 1.18, yielding an average-run-length of 50 (dashed red line). An
aberration, two standard deviations from baseline, was initially detected in January of 2000, with a CUSUM value of 1.37 and 51.5 myocardial
infarction-related hospitalization per 100,000 stays (solid line).
doi:10.1371/journal.pone.0000840.g001
COX-2 Inhibitors and MI
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launching of celecoxib. A second rise in November 2000 occurred
during the same month as the publication of the Vioxx
Gastrointestinal Outcomes Research (VIGOR) study.[31,32]
The exceedence vanished within one month of the withdrawal
of rofecoxib. The population-level findings, though based on
aggregated data, are used to confirm a hypothesis based on clinical
trial data [16] and to estimate the magnitude of the effect across
the population.
We used two approaches to identify the impact of the
prescriptions for COX-2 selective inhibitors. The first was to
simply treat each drug as a binary (present or absent) variable. We
find increases in inpatients stays for MI after the introduction of
rofecoxib and celecoxib. Second, we applied a correlational
approach to identify a dose-response relationship by modeling the
temporal fluctuations in inpatient stay for MIs with national
prescription rates. We find that adverse cardiovascular events
coincide best with the time period of population exposure to
rofecoxib and celecoxib. The analyses described are subject to the
known pitfalls of ecological studies, with caveats about inferring
causality.[33,34] However, our results are especially convincing
given the return to baseline following the market withdrawal of
rofecoxib and our confirmatory analysis. Further, this ecological
finding is confirming a prior suspected association.
Our study does have limitations. Our results, based only on an
inpatient population, may underestimate population-level rates of
Figure 2. Association between yearly prescriptions for rofecoxib and celecoxib and incidence of myocardial infarctions. A) Scatter plot reveals
the positive relationship between national prescriptions estimates for rofecoxib and celecoxib and hospitalizations due to myocardial infarction.
Prescriptions for rofecoxib and celecoxib peaked in 2001 with 52,466,000. Incidence of stays due to myocardial infarction also peaked in 2001 with
62.3 hospitalizations per 10,000. B) Line graphs show the interrupted time series of myocardial infarction-related hospitalizations. Prescriptions for
rofecoxib and celecoxib explained approximately 50.3 percent of the deviance in yearly variation of myocardial infarction related hospitalizations.
doi:10.1371/journal.pone.0000840.g002
Table 1. Yearly incidence in hospitalizations due to myocardial infarctions and corresponding national estimates of prescriptions
for rofecoxib and celecoxib.
..................................................................................................................................................
Year
Myocardial infarction-
related hospitalizations* Total inpatient{
Incidence of Myocardial
infarction-related
hospitalizations
(per 10000)1
Rofecoxib scripts
dispensed (millions){
Celecoxib scripts
dispensed (millions){
1997 3475 89638 48.8 0 0
1998 3654 93562 51.0 0 0
1999 3958 99047 55.0 4.84 17.54
2000 4357 105426 58.8 20.63 24.91
2001 4644 105603 62.3 25.41 27.06
2002 4627 107898 61.9 22.04 26.01
2003 4569 110735 61.1 19.83 23.65
2004 3923 110677 52.6 13.87 23.92
2005 3641 111751 48.8 0 14.27
*Unique patients hospitalized for a myocardial infarction, having being assigned a primary or admitting diagnosis of myocardial infarction (International Classification of
Diseases, Ninth Revision (ICD-9) code 410).
{Unique patients hospitalized at the Brigham and Women’s Hospital and Massachusetts General Hospital
{Total numbers of prescriptions dispensed were obtained from the freely available IMS Health annual report on Commonly Requested Therapeutic Class and Product
Information. Estimates are derived from a national prescription sales database.
1Incidence is calculated using the estimated underlying population market share coverage by both study hospitals
doi:10.1371/journal.pone.0000840.t001
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observations, narrowing confidence intervals for our rate ratio
estimates. However, these error calculations do not account for the
clustering of responses associated with temporal variation in risk.
The IMS prescription data were based on national estimates and
may not accurately represent possible local variation in Boston. For
instance,geographicvariationinprescriptionpracticesforrofecoxib
and celecoxib may have been disproportionately affected by media
attention regarding early reports of associated adverse cardiovas-
cular events. However, our use of yearly estimates should smooth
this potential bias. The prescription estimates also do not account
for continued use of the drug after its withdrawal from the market.
While part of the power of this approach stems from availability
of the full interrupted time series, including the period after market
withdrawal of rofecoxib, our findings highlight the importance of
understanding, modeling, and surveying for baseline adverse
outcomes to detect population-level aberrations from that baseline.
This study was performed with data from only two hospitals a in
single health care system, in a single city. In an active post launch
surveillance system, such signals will need to be rapidly evaluated
and adjudicated with replication in other data sets, in other
regions, and through multi-signal integration approaches.
High profile failures to detect safety problems during the pre-
approval period have brought new intense scrutiny on the drug
approval process.[35,36,37,38,39] Revelation of an association
between rofecoxib and MI [32,35,40,41] was a signal event
highlighting catastrophic failures in monitoring the safety of
therapeutics already on the market.[42] Because adverse effects of
drugs and therapeutics are often not detected in Phase III clinical
trials, [43] or they are suspected but not confirmed, a robust drug
safety system requires ongoing monitoring of adverse events
throughout the drug development lifecycle.[44] However, at
present, safety efforts are not balanced across the lifecycle.
There is no generally accepted process or gold standard set of
methods for identifying safety problems with drugs during the post
launch phase. A major vehicle for hypothesis generation is the
FDA’s Adverse Event Reporting System (AERS) which collects
voluntary reports[45] that are somewhat limited by poor quality,
under-reporting, and skewed and inadequate ascertain-
ment.[46,47,48,49] Nonetheless, AERS-based findings are often
the only basis for regulatory action.[49,50,51] Ultimately,
however, it impossible to correct for inherent data limitations.
Notably, in the earlier part of the decade, it would have been
very unlikely that a clinician would associate a MI with rofecoxib
and hence to report it to the AERS system. Likewise, a clinician
would have been unlikely to report a hip fracture in a patient
taking a proton pump inhibitor.[52] There is an emerging
consensus that semi-automated analysis of healthcare databases
is the next logical step.[21,22] Robust post-marketing surveillance
requires a multimodality approach to monitoring the health of
individuals using drugs and devices. As confirmatory evidence for
the veracity of a suspected association, use of a population
monitoring approach as an adjunct to pharmacovigilence methods
might have helped provide earlier support for the market
withdrawal of rofecoxib. Without a known prior association,
population health monitoring could help generate hypotheses
about candidate medication risk factors. This is especially
important for widely prescribed medications where there is
a substantial risk of population-level effects. If used prospectively,
however, to look across drugs at patterns of prescribing and
outcomes, careful attention would need to be paid to issues of
specificity and multiple testing.
Figure 3. Association between yearly prescriptions for rofecoxib and celecoxib and mean age of patients hospitalized for myocardial
infarctions. Line graph showing a significant negative association between mean patient age and national prescription volume for rofecoxib and
celecoxib (Spearman correlation, 0.67, P,0.05). Prescriptions for rofecoxib and celecoxib peaked in 2001 with 27,060,000 prescriptions dispensed
nationally while mean age was 64.6, the lowest in nine years.
doi:10.1371/journal.pone.0000840.g003
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